Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Agrigenetics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The action is handled by 1 examiner in 1 art unit, creating a focused examination path.
KUBELIK, ANNE R is the busiest examiner, with 1 pending matter. Immediate prosecution planning can center on that examiner’s treatment and the associated art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUBELIK, ANNE R | 1 | 75.8% | -0.8% |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19064220 | CRY1D FOR CONTROLLING CORN EARWORM | KUBELIK, ANNE R | 1663 | §102§103§112DP | Non-Final OA | — | Pending | Feb 26, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAgrigenetics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Anne R Kubelik has the most, with 1 of Agrigenetics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.